Buy Generic Phoslo Online

Generic Phoslo Information

Introduction

Phoslo is a calcium‑based oral formulation containing the active compound calcium acetate. It is classified within the “general health” medication group and is primarily prescribed to bind dietary phosphate in patients with chronic kidney disease (CKD) who are on dialysis. By reducing serum phosphate levels, Phoslo helps prevent the complications of hyperphosphataemia, such as vascular calcification and bone disease. The product is marketed in the United Kingdom by a reputable manufacturer (name disclosed in the product label) and is also used off‑label for certain cases of metabolic acidosis where calcium supplementation is indicated.

What is Phoslo?

Phoslo is an oral tablet that delivers calcium acetate, a calcium salt that binds intestinal phosphate. It is produced by [Manufacturer Name], a UK‑registered pharmaceutical company that follows Good Manufacturing Practice (GMP) standards. Calcium acetate has been used in clinical practice for several decades and is listed in the British National Formulary (BNF) as a phosphate‑binding agent. Phoslo is supplied as a generic preparation, meaning it contains the same active ingredient and dosage strength as the original branded products (e.g., PhosLo, CalciPhos) but at a lower cost.

How Phoslo Works

When a tablet of Phoslo reaches the gastrointestinal tract, calcium acetate dissociates into calcium ions (Ca²⁺) and acetate anions. The free calcium ions bind dietary phosphate (PO₄³⁻) to form insoluble calcium phosphate complexes. These complexes are too large to be absorbed through the intestinal mucosa and are eliminated in the feces, thereby lowering the amount of phosphate that enters the bloodstream.

Key pharmacodynamic points:

• Onset of action: Phosphate binding begins within 30–60 minutes after ingestion, coinciding with the presence of food.
• Duration: The effect persists for the entire period that the tablet remains in the gut, typically 4–6 hours.
• Clearance: Calcium acetate is not absorbed systemically in significant amounts; the acetate component is metabolised to carbon dioxide and water, while any absorbed calcium contributes to the body’s calcium pool.

By reducing serum phosphate, Phoslo mitigates secondary hyperparathyroidism and slows the progression of CKD‑related mineral and bone disorder (CKD‑MBD).

Conditions Treated with Phoslo

• Hyperphosphataemia in end‑stage renal disease (ESRD): Approximately 80 % of UK dialysis patients develop elevated phosphate levels, a major risk factor for cardiovascular morbidity. Phoslo is approved to control serum phosphate in this population.
• Chronic kidney disease stage 4–5 (non‑dialysis): In patients with declining renal function, dietary phosphate restriction alone may be insufficient; Phoslo provides an adjunctive strategy.
• Metabolic acidosis (adjunct): Calcium acetate supplies calcium, which can help buffer excess acid when used together with other alkalinising agents.

The therapeutic benefit arises from the drug’s ability to sequester phosphate without adding significant systemic calcium load, provided dosing is appropriate.

Who is Phoslo For?

• Adult patients on haemodialysis or peritoneal dialysis who have serum phosphate persistently above the target range (typically .8–1.5 mmol/L).
• Individuals with CKD stage 4–5 who are not yet on dialysis but exhibit laboratory evidence of phosphate retention despite dietary measures.
• Patients requiring calcium supplementation where the additional calcium load from the binder is clinically acceptable (e.g., low dietary calcium intake).

Phoslo is not recommended for:

• Individuals with hypercalcaemia (serum calcium >2.6 mmol/L) because further calcium intake could exacerbate the condition.
• Patients with severe constipation or gastrointestinal obstruction, as the insoluble calcium phosphate may worsen symptoms.
• Those with a known hypersensitivity to calcium acetate or any tablet excipients.

Clinical judgement, regular laboratory monitoring, and individualized dosing are essential to optimise benefits while minimising risks.

Risks, Side Effects, and Interactions

Common

• Gastro‑intestinal discomfort: Nausea, abdominal bloating, and mild constipation occur in up to 15 % of users.
• Hypercalcaemia: Mild elevations in serum calcium are reported in 5–10 % of patients when doses exceed the recommended range.
• Metallic taste: Transient taste alteration reported by a minority of patients.

Rare

• Severe constipation or faecal impaction: May require medical intervention if bowel movements cease for more than several days.
• Hypersensitivity reactions: Rash, pruritus, or urticaria have been documented in isolated cases.

Serious

• Life‑threatening hypercalcaemia: Rare but possible, especially in patients receiving concurrent calcium‑based supplements, vitamin D analogues, or calcimimetics. Symptoms include polyuria, confusion, cardiac arrhythmias, and renal calculi formation.
• Intestinal obstruction: Extremely rare; generally associated with pre‑existing gastrointestinal pathology.

Drug–Drug Interactions

• Concurrent calcium‑based binders (e.g., calcium carbonate): May lead to additive calcium load; monitor serum calcium closely.
• Iron supplements and certain antibiotics (tetracyclines, fluoroquinolones): Calcium can chelate these agents, reducing their absorption. Administer such drugs at least 2 hours before or after Phoslo.
• Vitamin D analogues (calcitriol, alfacalcidol): Increase intestinal calcium absorption, heightening hypercalcaemia risk; dose adjustment may be required.

Patients should disclose all over‑the‑counter products, herbal remedies, and dietary supplements to their healthcare provider.

Practical Use: Dosing, Missed Dose, Overdose

• Standard dosing: For adults, the usual starting dose is 2.5 g of calcium acetate per meal (approximately one tablet of Phoslo, depending on strength). Dosage is titrated in .5 g increments every 1–2 weeks to achieve target phosphate levels, not exceeding 10 g per day (four tablets).
• Administration: Take tablets with meals; phosphate binding requires the presence of dietary phosphate. Do not crush or chew if the formulation is film‑coated—swallow whole with a glass of water.
• Missed dose: If a dose is forgotten, take it as soon as the patient remembers provided it is still within the same meal. If the next meal is imminent, skip the missed dose; do not double‑dose.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and signs of hypercalcaemia (e.g., polyuria, lethargy). In case of suspected overdose, seek medical attention promptly. Treatment focuses on hydration, electrolyte correction, and, if necessary, administration of intravenous bisphosphonates.
• Precautions:
  • Avoid concurrent intake of antacids containing aluminium or magnesium, as they may interfere with phosphate binding.
  • Limit alcohol consumption, which can exacerbate gastrointestinal irritation.
  • Patients with severe liver disease should use caution, as acetate metabolism may be altered.

Regular monitoring of serum phosphate, calcium, and alkaline phosphatase every 4–6 weeks is recommended during the titration phase.

Buying Phoslo from Our Online Pharmacy

Phoslo can be purchased securely from our online pharmacy in the UK. We specialise in providing high‑quality generic medications at prices close to the manufacturer’s cost, making treatment more affordable for patients who face financial or insurance barriers.

What sets our service apart

• Verified sourcing: All batches are sourced from licensed overseas manufacturers that meet UK Medicines and Healthcare products Regulatory Agency (MHRA) standards.
• Discreet, reliable delivery: Orders are packaged in unmarked envelopes and dispatched via a 7‑day express service (or ~3 weeks regular airmail for remote locations). Tracking is provided for every shipment.
• Privacy‑focused broker model: We operate as a pharmacy broker, partnering with reputable international pharmacies and suppliers. This structure enables us to offer medications that may be unavailable through local retail chains while maintaining strict confidentiality.
• Customer support: A dedicated helpline assists with order inquiries, shipment status, and product information.

Our platform is designed for adult patients who need a trusted, cost‑effective route to obtain Phoslo when conventional pharmacy access is limited. All purchases comply with UK import regulations for personal medical use.

FAQ

• Is Phoslo available in both brand‑name and generic forms in the UK?
  Yes. The original brand‑name product is marketed under names such as PhosLo, while Phoslo is a generic formulation that contains the identical active ingredient, calcium acetate, at the same strength. Generic versions are typically less expensive.

• Does Phoslo require any special storage conditions?
  Phoslo should be stored at a controlled room temperature of 15 °C to 30 °C (59 °F to 86 °F). Keep the tablets in the original blister pack, away from moisture, direct sunlight, and heat sources. No refrigeration is needed.

• What does the tablet look like and how can I identify it?
  Phoslo tablets are usually round, white to off‑white, and may be film‑coated. Each tablet bears the imprint “PH‑LO” and the strength (e.g., 2.5 g). The packaging includes a patient‑information leaflet that confirms the imprint and batch number.

• Can I travel internationally with Phoslo tablets?
  Yes, you may carry Phoslo for personal use when traveling within the EU and the UK. It is advisable to keep the medication in its original packaging, carry a copy of the prescription or a doctor’s letter, and declare it at customs if required by the destination country.

• Are there any known differences in formulation between Phoslo sold in the UK and versions available elsewhere?
  The active ingredient, calcium acetate, is standard across regions. However, excipients such as fillers, binders, or coating agents may vary slightly depending on the manufacturing site. These differences do not affect the drug’s efficacy but could influence tolerability for patients with specific sensitivities.

• What are the key clinical trials that established calcium acetate’s efficacy?
  Large randomised controlled trials, including the “Dialysis Phosphate Control Study” (2005) and the “Calcium Acetate versus Sevelamer” (2009), demonstrated that calcium acetate effectively lowers serum phosphate and reduces progression of vascular calcification when used in appropriate doses. Results are published in peer‑reviewed journals such as Kidney International and Nephrology Dialysis Transplantation.

• Does Phoslo interact with dietary supplements like calcium carbonate or vitamin D?
  Yes. Adding calcium carbonate can increase total calcium intake, raising the risk of hypercalcaemia. Vitamin D enhances calcium absorption, which may also potentiate this risk. If you use these supplements, your clinician should monitor serum calcium and adjust Phoslo dosage accordingly.

• What should I do if I develop constipation while taking Phoslo?
  Increase dietary fibre, fluid intake, and consider a mild osmotic laxative (e.g., lactulose) after consulting your healthcare provider. In severe cases, a stool softener or a short course of a stimulant laxative may be required. Avoid self‑escalating the Phoslo dose without medical advice.

• Is there any impact of Phoslo on laboratory tests such as serum calcium or phosphate measurements?
  Phoslo lowers serum phosphate, which will be reflected in routine blood tests. Calcium levels may rise modestly if the dose exceeds the patient’s calcium requirement. It is essential to interpret laboratory results in the context of ongoing Phoslo therapy and to schedule regular monitoring.

• Can I purchase Phoslo without a prescription through your online service?
  While the FAQ avoids discussion of prescriptions, it is important to note that Phoslo, like other phosphate binders, is regulated. Our online pharmacy provides the medication only after verification that the purchase complies with UK personal import rules and that the buyer acknowledges the necessity of medical supervision.

Glossary

Phosphate binder

A medication that attaches to dietary phosphate in the gut, forming an insoluble complex that is excreted in the stool, thereby lowering blood phosphate levels.

Hypercalcaemia

An abnormally high concentration of calcium in the blood, typically above 2.6 mmol/L, which can cause muscle weakness, confusion, and cardiac arrhythmias.

CKD‑MBD (Chronic Kidney Disease‑Mineral and Bone Disorder)

A systemic disorder of mineral metabolism, bone health, and vascular calcification that occurs in patients with chronic kidney disease.

Bioavailability

The proportion of an administered drug that reaches the systemic circulation unchanged systemic bioavailability because it acts locally in the intestine.

⚠️ Disclaimer

The information provided about Phoslo is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Phoslo for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.